logo
Federal judge blocks Trump administration from defunding Planned Parenthood

Federal judge blocks Trump administration from defunding Planned Parenthood

Fox News4 days ago
A judge on Monday temporarily blocked the Trump administration from stripping Medicaid funds from Planned Parenthood after Congress and President Donald Trump agreed to partially defund the nonprofit through passage of the One Big Beautiful Bill Act.
Judge Indira Talwani of the U.S. District Court for the District of Massachusetts said in her order partially granting a preliminary injunction that the bill unconstitutionally punishes Planned Parenthood member organizations that do not provide abortions.
The injunction will risk "at most minimal harm—financial or otherwise—to" the Trump administration while the lawsuit proceeds," Talwani, an Obama appointee, wrote.
Talwani's order arose from a lawsuit brought by Planned Parenthood, the nation's largest abortion vendor, over the One Big Beautiful Bill Act, a massive budget bill that passed Congress this month with no Democrat support. Trump signed the bill into law on July 4.
A provision in the bill stripped Medicaid funding from Planned Parenthood, which the nonprofit said could force it to close about 200 of its 600 facilities and deprive about half of its customers, more than one million people, of services that do not include abortion.
Planned Parenthood attorneys noted in court filings that Medicaid does not cover abortion.
The attorneys argued that cancer and sexually transmitted infections would go undetected, especially for low-income people, and that more unplanned pregnancies would occur because of a lack of contraception access. They said the consequences of losing Medicaid funding "will be grave."
Department of Justice (DOJ) attorneys had previously argued in court filings that the purpose of the budget provision was to stop "federal subsidies for Big Abortion" by freezing federal funds for certain Medicaid recipients who provide abortions. Weakening Planned Parenthood has been one of the pro-life movement's leading priorities since the Supreme Court overturned Roe v. Wade.
Talwani granted a temporary restraining order two weeks ago in favor of Planned Parenthood. The judge initially offered no explanation for her decision, a move that led to widespread backlash among Republicans who described it as judicial overreach. Days later, Talwani offered more context in a subsequent order.
The preliminary injunction will leave in place the pause on defunding Planned Parenthood indefinitely, but the Trump administration is likely to appeal the order to the U.S. Court of Appeals for the First Circuit.
DOJ attorneys had previously argued to the court that blocking a measure that was passed by Congress and signed by the president was an extraordinary move and unjustified.
"Beyond the futility of the claims on the merits, Planned Parenthood fails to demonstrate imminent irreparable harm to justify an injunction, asserting only classically reparable economic injury and irrelevant potential harm to patients, who are third parties not before this Court," DOJ attorneys wrote.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

Yahoo

time9 minutes ago

  • Yahoo

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

Yahoo

time9 minutes ago

  • Yahoo

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Maxwell is talking 'about everybody' in meetings with the deputy attorney general.
Maxwell is talking 'about everybody' in meetings with the deputy attorney general.

Yahoo

time9 minutes ago

  • Yahoo

Maxwell is talking 'about everybody' in meetings with the deputy attorney general.

Revelations could be near at hand in the Jeffrey Epstein saga as Ghislaine Maxwell has been granted limited immunity to speak freely in her meetings with Deputy Attorney General Todd Blanche. Blanche traveled to the Tallahassee, Florida, prison where the convicted accomplice of late sex offender Jeffrey Epstein is serving a 20-year sentence, for a nine-hour interview over two days. ABC News first reported on the limited immunity, meaning Maxwell can disclose information without criminally implicating herself. 'She answered questions about everybody,' attorney David Oscar Markus told reporters on Friday evening. The meetings were reportedly initiated by Maxwell herself.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store